Rigel Pharmaceuticals, Inc.
corporate_fare Company Profile
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for RIGL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for RIGL spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Rigel Q3 EPS Misses at $0.65 as Launch Costs Weigh, Revenue Tops Estimates
- Rigel Q3 Revenue Rises to $80.9M on VEPPANU Launch; Net Income Falls to $13.2M
- Rigel Reports Strong Q2 with $67M Net Product Sales, Raises 2026 Revenue Guidance to $285-$295M
- Rigel Posts Record Q2 Product Sales, Raises 2026 Revenue Outlook to $295M
- Rigel Pharmaceuticals Appoints New Chief Medical Officer, Former CMO Departs
Financial Snapshot
Short Interest & Short Volume
12.93 days to coverFINRA reported short interest of 2,535,665 shares in RIGL as of the October 30, 2026 settlement, a 7.2% decrease from the prior period — about 12.9 days to cover at its recent average daily volume. On November 20, 2026, 46.4% of RIGL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.